31 May 2024
By Ronny Allan
0 Comments
NHS England’s new Cancer Vaccine Launch Pad

NHS England’s new Cancer Vaccine Launch Pad

Clinical Trials and Research, Patient Advocacy, Treatment,
Update August 2025.  Patients in England with advanced head and neck cancer are being fast-tracked into a ground-breaking mRNA cancer vaccine trial, as the NHS expands its Cancer Vaccine Launch Pad (CVLP) to accelerate access to cutting-edge treatments. Update April 2025.  Melanoma patients in England get fast-track access to cancer vaccineUpdate March 2025. The UK government announced their intention to abolish NHS England and bring it back under the Department for Health and Social Care (DHSC) (i.e. a merger).  The change programme will take up to 2 years.  In the meantime, the blog will be updated with new nomenclature when further information is…
Read More
22 May 2021
By Ronny Allan
2 Comments
Clinical Trial Phase 2: Survivin Long Peptide Vaccine (SurVaxM) with Temozolomide in Treating Patients With Grade 3 Neuroendocrine Neoplasms

Clinical Trial Phase 2: Survivin Long Peptide Vaccine (SurVaxM) with Temozolomide in Treating Patients With Grade 3 Neuroendocrine Neoplasms

Clinical Trials and Research, , , , , ,
Update 5th May 2026. Biotechnology company MimiVax Inc. and Roswell Park Comprehensive Cancer Center today jointly announced the launch of a phase 2 clinical trial (NCT06202066) evaluating SurVaxM in combination with temozolomide in patients with progressing neuroendocrine tumours, also known as NETs. The study is being conducted at Roswell Park in Buffalo, New York, under the direction of principal investigator Dr. Jasmeet Kaur.This trial has changed course. It started in 2021 as a phase 1 trial for NETs.  A separate trial then added Temozolomide as a combo treatment. Then Phase 2 of the clinical trial gathered all the data and the original trial continues with the…
Read More